79858s36501
NM_001146003.1 NM_001321220.1 NM_001321221.1 NM_001321223.1 NM_001321224.1 NM_024800.4 NM_145910.3 XM_011513167.2 XM_011513173.1 XM_011513174.1 XM_011513175.1 XM_011513181.1 XM_017007205.1 XM_017007206.1 XM_017007207.1 XM_017007208.1 XM_017007209.1 XM_017007210.1 XM_017007211.1 XM_017007212.1 XM_017007213.1 XM_017007214.1 XM_017007215.1 XM_017007216.1 XM_017007218.1 XM_017007219.1 XM_017007220.1 XM_017007221.1 XM_017007222.1 XM_017007224.1 XM_017007225.1 XM_017007226.1 XM_017007227.1 XM_017007228.1 XM_017007231.1 XM_017007232.1 XM_017007233.1
19%(+/-2% mRNA remaining)(HeLa cell line) [TaqMan® Assay ID: Hs00380328_m1]
HeLa cells were reverse transfected with 5nM gene-specific Silencer® Select siRNA or 5nM Silencer® Select Negative Control #2 siRNA. 48 hours post-transfection, gene expression analysis was performed using the TaqMan® Gene Expression Cells-to-CT Kit and appropriate TaqMan® Gene Expression Assays. 18S rRNA was used as an endogenous control. Validation results are expressed as average percent mRNA remaining, relative to Negative Control siRNA-treated samples, along with the standard deviation of multiple independent experiments.